ALK and renal cell carcinoma: ALK fusion proteins have also been described in NSCLC, diffuse large B-cell lymphoma (DLBCL), inflammatory myofibroblastic tumour (IMT), and to a lesser extent oesophageal squamous cell carcinoma (ESCC), renal medulla carcinoma (RMC), renal cell carcinoma (RCC), serous ovarian carcinoma (SOC), and breast and colon cancer [18,118].